tirzepatide on shortage list Lilly's weight-loss drug removed from FDA's Wegovy off shortage list :

doi: 10.1016/j.atherosclerosis.2015.05.005 144 TuttolomondoA.Di RaimondoD.PecoraroR.ArnaoV.PintoA.LicataG

ISO 9001:2015 facility used

Current clinical consensus reflects the following: Research findings are preliminary and insufficient to guide treatment decisions No regulatory approval exists for using GLP-1s in addiction treatment Early signals do not outweigh the lack of long-term outcome data Instead, clinicians continue to recommend established, evidence-based approaches, including: Behavioral therapies tailored to substance use disorders Medication-assisted treatment when medically indicated Comprehensive psychosocial support and relapse-prevention planning Comprehensive assessment remains a cornerstone of safe and effective care

If that is what someone is looking for, InfiniWell is one of the more interesting brands in the space right now

References include the Novo Nordisk Ozempic prescribing information (rev